Vertex Pharmaceuticals traded at $292.20 this Friday September 30th, decreasing $0.60 or 0.20 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals lost 3.71 percent. Over the last 12 months, its price rose by 62.02 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 275.00 by the end of this quarter and at 251.14 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
292.20
Daily Change
-0.20%
Yearly
62.02%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 135.16 -7.56 -5.30% 23.90%
Acadia Pharmaceuticals 16.55 0.41 2.54% -5.32%
Acorda Therapeutics 0.29 0.01 4.84% -93.75%
Agios Pharmaceuticals 29.41 0.84 2.94% -36.53%
Alnylam Pharmaceuticals 214.40 5.01 2.39% 11.27%
Amgen 227.30 -1.11 -0.49% 6.25%
Arrowhead Research 34.95 1.67 5.02% -44.02%
Biogen 268.45 4.17 1.58% -5.46%
Bluebird Bio 6.40 0.70 12.28% -66.51%
BioMarin Pharmaceutical 86.50 1.44 1.69% 11.92%
Bristol-Myers Squibb 71.83 0.12 0.17% 20.70%
Gilead Sciences 62.59 -0.48 -0.76% -8.71%
Intercept Pharmaceuticals 13.44 -2.97 -18.10% -9.49%
Incyte Corp 67.71 1.10 1.65% -0.73%
Insmed 22.07 0.20 0.91% -19.86%
Ionis Pharmaceuticals 44.91 0.63 1.42% 33.90%
J&J 164.67 0.14 0.09% 2.62%
Merck & Co 86.90 0.26 0.30% 6.76%
Moderna Inc 121.56 3.49 2.95% -64.36%
Neurocrine Biosciences 103.96 1.20 1.17% 8.39%
Novartis 75.56 0.64 0.85% -0.66%
Puma Biotechnology 2.35 0.03 1.29% -66.48%
Pfizer 44.35 0.19 0.43% 3.12%
PTC Therapeutics 51.78 1.43 2.84% 37.24%
Ultragenyx Pharmaceutical 42.80 2.25 5.55% -51.25%
Regeneron Pharmaceuticals 700.02 8.20 1.19% 22.64%
Roche Holding 322.80 2.55 0.80% -6.50%
Sanofi 78.62 0.78 1.00% -4.83%
Seattle Genetics 137.29 1.59 1.17% -20.74%
Sangamo BioSciences 5.04 0.17 3.39% -45.63%
Sarepta Therapeutics 111.74 2.11 1.92% 16.34%
United Therapeutics 207.53 -0.42 -0.20% 11.63%
Vertex Pharmaceuticals 292.20 -0.60 -0.20% 62.02%

Indexes Price Day Year
US500 3648 8.15 0.22% -16.26%
USND 10869 131.66 1.23% -25.38%
US400 2248 29.71 1.34% -16.22%
USNDX 11204 39.16 0.35% -24.26%

Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.